ORIC
Oric Pharmaceuticals, Inc. Common StockstockNASDAQ
oric pharmaceuticals, inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers. its lead product candidate is oric-101, a small molecule antagonist of the glucocorticoid receptor, which has been linked to resistance to multiple classes of cancer therapeutics across various solid tumors. the company's second product candidate is oric-533, an orally bioavailable small molecule inhibitor of cd73 being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens. it is also developing multiple precision medicines targeting other cancer resistance mechanisms. the company was founded in 2014 and is headquartered in south san francisco, california.
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 8.50 | 2026-11-12 | -10.23% | -1.781 |
| 1M | 12.72 | 2026-10-19 | -40.02% | 0.840 |
| 3M | 14.65 | 2026-08-19 | -47.92% | 0.870 |
| 6M | 7.97 | 2026-05-19 | -4.27% | 1.572 |
| 1Y | 11.48 | 2025-11-19 | -33.54% | 1.312 |
| 2Y | 8.89 | 2024-11-19 | -14.17% | — |
| 5Y | 16.50 | 2021-11-19 | -53.76% | 1.223 |
Oric Pharmaceuticals, Inc. Common Stock (NASDAQ:ORIC) stock price today is $7.63, and today's volume is 1,385,241. ORIC is down 4.625% today. The 30 day average volume is 1.81M. ORIC market cap is $793.00M with 103.93M shares outstanding.